February 20, 2007 -- Shire offered $2.6 billion to buy New River Pharma, its partner on an ADHD drug; BioMarin fell on news that 6R-BH4 failed a Phase IIa trial for hypertension; Roche out-licensed the ex-US rights for its OTC weight-loss drug Alli to GlaxoSmithKline; Medarex sold 2.5 million shares of Genmab A/S to raise $150 million; Auxilium said AA4500 was effective against Dupuytren’s contracture; Amgen took a 3% hit last week because of concerns about Aranesp; Novartis slipped on worries its effort to win FDA approval of Galvus, its diabetes drug, would be delayed; MedImmune reaffirmed its plan to remain an independent company, despite hedge fund pressure; and Edwards received an FDA letter about quality control problems. The Centient Biotech 200™ gained 15 points to end at 4068, a rise of .34%. More details...
